Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update

Neuronetics, Inc. (NASDAQ:STIM) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 312,900 shares, a decline of 35.8% from the December 15th total of 487,400 shares. Currently, 2.0% of the shares of the stock are sold short. Based on an average trading volume of 413,300 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Investors Weigh In On Neuronetics

Several hedge funds have recently modified their holdings of the company. David J Yvars Group lifted its stake in shares of Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after buying an additional 14,825 shares during the period. Gabelli Funds LLC lifted its stake in shares of Neuronetics by 88.2% during the 2nd quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock worth $86,000 after purchasing an additional 22,500 shares during the period. Landscape Capital Management L.L.C. purchased a new position in shares of Neuronetics during the 3rd quarter worth $53,000. GSA Capital Partners LLP boosted its holdings in shares of Neuronetics by 64.5% during the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after purchasing an additional 30,837 shares during the last quarter. Finally, HighTower Advisors LLC grew its position in shares of Neuronetics by 55.5% in the third quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock valued at $187,000 after purchasing an additional 87,816 shares during the period. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Price Performance

Shares of NASDAQ:STIM traded down $0.05 on Thursday, hitting $2.28. The company had a trading volume of 537,118 shares, compared to its average volume of 1,490,912. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90. The company has a market cap of $69.20 million, a PE ratio of -1.85 and a beta of 2.11. Neuronetics has a 52-week low of $0.52 and a 52-week high of $5.07. The business has a 50 day moving average of $1.25 and a 200 day moving average of $1.22.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.